

Pidilizumab

Catalogue No.: abx831270

Pidilizumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting PDCD1/CD279, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.

Pidilizumab is under investigation in clinical trial NCT01952769 (Anti PD1 Antibody in Diffuse Intrinsic Pontine Glioma).

Target:	PDCD1/CD279
Research Area:	Humanized Monoclonal Antibodies, Biosimilars
Clonality:	Monoclonal
Reactivity:	Human
Expression:	Recombinant
Tested Applications:	ELISA, WB
Host:	Human
Recommended dilutions:	Optimal dilutions/concentrations should be determined by the end user.
Conjugation:	Unconjugated
Isotype:	IgG ₁ , Kappa
Form:	Liquid
Purity:	> 95%
Purification:	Purified from cell culture supernatants by Protein A/G chromatography.
Storage:	Store at 4°C for up to 2 weeks. Aliquot and store at -20°C for long term storage. Avoid repeated freeze/thaw cycles.
Shelf Life:	12 months.
Buffer:	0.01 M PBS. pH 7.4.
CAS Number:	1036730-42-3

Datasheet

Version: 3.0.0

Revision date: 09 Feb 2026



Concentration: Batch-dependent, typically between 0.5-2.0 mg/ml.

Note: THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION.

For Reference Only